ABBV Mar 2024 160.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:44PM EDT. Market open.
| Previous close | 6.30 |
| Open | 5.76 |
| Bid | 5.75 |
| Ask | 5.95 |
| Strike | 160.00 |
| Expiry date | 2024-03-15 |
| Day's range | 5.35 - 5.81 |
| Contract range | N/A |
| Volume | |
| Open interest | 850 |
ZacksAbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
Simply Wall St.AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights AbbVie's estimated fair value is US$243 based on 2 Stage Free Cash Flow to Equity Current share price of...
ZacksAbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV) closed at $154.65 in the latest trading session, marking a +1.25% move from the prior day.
© 2023 Yahoo. All rights reserved.
